Last checked at 11 Jun 2021 14:57
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 10 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 4,020,602 6.06
| 735,400 1.11
| ||||
(2) Derivatives (other than options) | 553,774 0.83 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 4,574,376 6.89
| 735,400 1.11
| ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Sale (Borrow Return)
Sale (New Loan)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 211,600
16,700
100 300 100 99 900 199 101 400 400 8,487 400 597 290 17,664 160 2,200 36,477 500 200 300 4,690 2,671 16,699 3,580 600 4,473 3,604 300 300 200 500 300 1,500 500 780 200 1,536 1,400 400 700 200 300 900 800 200
100 400 100 200 200 99 1,800 199 101 400 599 400 3,458 400 1,399 412 900 200 3,279 36,477 500 200 600 300 300 16,699 300 4,265 559 600 800 300 300 200 900 500 300 701 1,300 200 700 2,300 500 400 800 500 700 200 300 1,200 1,300 300 | N/A
N/A
4.0400 USD 4.0300 USD 4.0200 USD 4.0100 USD 4.0000 USD 3.9950 USD 3.9925 USD 3.9850 USD 3.9700 USD 3.9600 USD 3.9575 USD 3.9500 USD 3.9476 USD 3.9420 USD 3.9413 USD 3.9400 USD 3.9385 USD 3.9380 USD 3.9375 USD 3.9358 USD 3.9350 USD 3.9344 USD 3.9338 USD 3.9337 USD 3.9333 USD 3.9303 USD 3.9300 USD 3.9267 USD 3.9258 USD 3.9250 USD 3.9240 USD 3.9233 USD 3.9200 USD 3.9160 USD 3.9158 USD 3.9150 USD 3.9110 USD 3.9100 USD 3.9050 USD 3.9000 USD 3.8950 USD 3.8933 USD 3.8900 USD 3.8800 USD 3.8700 USD
4.0400 USD 4.0300 USD 4.0200 USD 4.0163 USD 4.0150 USD 4.0100 USD 4.0000 USD 3.9950 USD 3.9925 USD 3.9850 USD 3.9816 USD 3.9700 USD 3.9600 USD 3.9575 USD 3.9528 USD 3.9500 USD 3.9456 USD 3.9450 USD 3.9400 USD 3.9385 USD 3.9380 USD 3.9375 USD 3.9367 USD 3.9358 USD 3.9350 USD 3.9338 USD 3.9333 USD 3.9300 USD 3.9282 USD 3.9279 USD 3.9275 USD 3.9267 USD 3.9258 USD 3.9250 USD 3.9242 USD 3.9240 USD 3.9233 USD 3.9230 USD 3.9200 USD 3.9150 USD 3.9114 USD 3.9100 USD 3.9060 USD 3.9050 USD 3.9025 USD 3.9020 USD 3.9000 USD 3.8950 USD 3.8933 USD 3.8900 USD 3.8800 USD 3.8700 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 36,477 | 3.9385 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating to the voting rights of any relevant securities under any option referred to
on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 11 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |